Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., has been re-certified as a high-tech enterprise, allowing it to continue paying a corporate income tax rate of 15% from 2025 to 2027 [1] Group 1 - The re-certification was conducted by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the State Taxation Administration of Guangdong Province [1]

（编辑 姚尧） 证券日报网讯 2月6日，五粮液在互动平台回答投资者提问时表示，公司高度重视中小投资者权益，近 年来通过持续加大分红力度、承诺三年期分红、股东优惠购酒等方式积极回馈广大投资者。对于资金使 用，公司始终坚持在保障资金安全、保障生产经营秩序前提下，充分发挥资金优势，多维度使用资金， 在当前环境下，公司需保有充足的资金来应对可能出现的市场挑战以及保障可持续的股东回报。 ...

Core Viewpoint - The company, Suihengyun A, is positioning itself as a comprehensive operator in the energy and new energy sectors, aligning with national energy development trends and the "dual carbon" strategic goals [1] Group 1: Business Strategy - The company is actively seeking suitable development opportunities within the energy industry chain [1] - It aims to identify high-quality investment targets to foster new profit growth points [1]

证券日报网讯 2月6日，鸿铭股份发布公告称，公司于2026年2月6日召开了2026年第二次临时股东会， 审议通过了《关于董事会换届选举第四届董事会非独立董事的议案》《关于董事会换届选举第四届董事 会独立董事的议案》，同意选举金玺、王佩仪、刘江为公司第四届董事会非独立董事；同意选举钟水 东、左英魁、朱智伟为公司第四届董事会独立董事。 （编辑 任世碧） ...

本报讯 （记者王镜茹）2月6日，记者从中国出口信用保险公司深圳分公司（以下简称"中国信保深圳分 公司"）了解到，2025年该公司主动融入国家对外开放战略大局，持续创新信用保险产品与服务模式， 为深圳企业"走出去"保驾护航，2025年全年承保深圳地区外贸出口规模超1100亿美元，同比增长15%； 累计支付赔款近13亿元，同比增长36%；服务各类外贸企业超3万家，切实发挥了外贸"稳定器""安全 网"的重要作用，为产业链供应链安全稳定注入了强劲动能。 中国信保深圳分公司副总经理徐甜介绍说，中国信保深圳分公司始终坚持以服务国家战略为己任，将政 策性职能与共建"一带一路"倡议、产业链供应链安全、普惠金融等国家重大部署紧密结合。2025年，该 公司承保深圳企业向"一带一路"共建国家出口和投资金额超520亿美元，同比增长42%。为深圳多家龙 头通信企业提供中长期出口卖方信贷保险服务，助力当地数字基础设施升级和经济社会数字化转型。通 过创新中长期出口信用保险与海外投资保险方案，为关键企业提供了稳定可靠的风险保障，有效助力中 国技术、中国标准和中国装备"出海"。 该公司还着力化解中小微外贸企业面临的出海"信息不对称"与"融资难 ...

证券日报网讯 2月6日，三木集团发布公告称，截至2026年2月6日，公司及控股子公司对外担保余额为 9，000万元；母公司为全资子公司担保余额为327，197万元；母公司为控股子公司担保余额为93，170 万元；公司上述三项担保合计金额为429，367万元，占公司最近一期经审计净资产的比例为422.14%。 上述对外担保事项中，无逾期担保。 （编辑 袁冠琳） ...

Core Viewpoint - Xiamen Xiangyu announced plans to provide guarantees for its subsidiaries and affiliated companies, with a total guarantee amount not exceeding RMB 194 billion for the year 2026 [1] Group 1 - The company will hold its 10th Board of Directors' third meeting on February 5, 2026, to review the proposal for the guarantee amount [1] - The guarantee will be provided through credit or self-owned asset pledges to meet the operational needs of subsidiaries and certain affiliated companies [1] - The guarantee amount will be managed under the approved limit until the shareholders' meeting in 2027, which will review the guarantee amount for that year [1] Group 2 - The shareholders' meeting will authorize the company's legal representatives to sign relevant guarantee documents within the approved limit [1] - The authorization will be effective from the date of approval at the 2026 shareholders' meeting until the approval of the guarantee amount at the 2027 shareholders' meeting [1]

Core Viewpoint - The company emphasizes its commitment to investor returns and trust, having implemented a stable dividend policy for nine consecutive years since 2016, consistently providing cash dividends to investors [1] Group 1: Dividend Policy - The company has maintained a robust dividend policy, returning cash dividends to investors for nine years [1] - The company highlights its focus on investor communication and transparency, allowing all legitimate investor opinions to be conveyed through legal channels [1] Group 2: Financial Communication - The company acknowledges that different third-party trading software may have varying calculations for financing amounts due to multiple rounds of mergers and acquisitions [1] - Investors are advised to refer to the company's official disclosures for accurate financial information [1]

（编辑 王雪儿） 证券日报网讯 2月6日，萤石网络在互动平台回答投资者提问时表示，公司拥有自主研发的面向垂直物 联场景的、支持端云协同的MoE具身大模型"萤石蓝海大模型"。萤石蓝海大模型更专注于垂直物联场 景，接入的物联设备多种多样，能够感知物理世界空间信息，处理多模态数据并进行识别与理解，最终 指导设备做出响应。 ...

Core Viewpoint - The company is currently experiencing short-term profit impacts due to increased investments in new product development and global expansion, but management remains focused on enhancing core competitiveness through innovation in the biopharmaceutical sector to achieve sustainable high-quality growth [1] Group 1 - The company is investing heavily in new product layouts and global expansion, which is affecting net profit in the short term [1] - Management emphasizes a commitment to focusing on the biopharmaceutical core business and deepening innovation-driven strategies [1] - The goal is to continuously improve the company's core competitiveness for stable and high-quality development in the long run [1]